Multiple sclerosis: time for early treatment with high-efficacy drugs.

ABSTRACT: This review addresses current changes in the approach to treating patients with multiple sclerosis (MS). The widely practiced approach of utilizing agents with lower treatment efficacy (LETA) at onset with subsequent escalation has been challenged by new data suggesting that MS patients derive greater benefit when therapy is initiated with high-efficacy treatment agents (HETA). Several recent studies compared treatment efficacy and safety of early administration of HETA versus LETA. The results of randomized, double blind, phase III studies with LETA as a control arm and population-based larger and longer studies using propensity scoring, marginal structural modeling and weighted cumulative exposure analysis support the benefit of early treatment with HETA. Patients initiating their treatm

SUBMITTER: Selmaj K 

PROVIDER: S-EPMC10769939 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature